The Biden administration is proposing Medicare and Medicaid coverage for glucagon-like peptide 1 receptor agonist (GLP-1 RA) ...

Millions of obese Americans would get access to popular weekly injectables that would help them shed pounds quickly if a $35 ...

It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.

Mounjaro is a treatment for Type 2 diabetes that activates GIP and GLP-1 pathways to help regulate blood sugar. It’s part of ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

The stocks of companies that make the new class of drugs to treat obesity and manage diabetes were higher across the board ...

Millions of Americans with obesity would be eligible to have popular weight-loss drugs like Wegovy or Zepbound covered by ...

Today, Mounjaro and Zepbound both have become blockbusters, and in the most recent quarter, they generated $3.1 billion and ...

More than seven million additional Americans could get coverage for popular drugs such as Zepbound and Wegovy under the ...

Novo Nordisk's Wegovy and similar drugs could see their costs significantly reduced under this plan, making them more ...

About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce ...

The White House said it's moving to make the federal health insurance plans pay for anti-obesity drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound for people who are obese, even if they don ...